Akari enrols seven out of nine patients in bullous pemphigoid trial
Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far enrolled seven out of its...
Trending menu:
-
![Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane]()
Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane
-
![AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial]()
AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial
-
![The most researched drugs in cystic fibrosis trials]()
The most researched drugs in cystic fibrosis trials
-
![Improved clinical efficacy found wanting in Phase III IMPALA trial]()
Improved clinical efficacy found wanting in Phase III IMPALA trial
-
![New, efficacious options offer hope for Ebola treatment and containment]()
New, efficacious options offer hope for Ebola treatment and containment
-
![GSK’s Zejula meets primary goal in Phase III ovarian cancer trial]()
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
Expert commentary & analysis from GlobalData
Chasing Cancer considers how to improve patient access to cancer therapies
First-in-class HIF-2a inhibitor could revolutionise renal cell carcinoma treatment algorithm
Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis
Stivarga’s potential in combination therapy for metastatic colorectal cancer
Most Read
Company releases
Industry Leaders Come on Board as NMiTE Adds Engineering Expertise
The New Model in Technology and Engineering (NMiTE) has announced three appointments to its Board of Trustees.
Inocure at Electrospin, China
See Malvern Panalytical’s Upcoming Webinars
Malvern Panalytical has announced its next round of webinars. Find out more below. If you are interested in attending any...
Pfanstiehl to Attend Two Events in August
Almac Group Launches Almac Adapt: A New Patient-centric Supply Solution
Almac Clinical Services has announced the launch of Almac Adapt, an innovative Just in Time...
Company whitepapers
Primary Cells Isolated from Healthy Human and Animal Tissues
Caltag MedsystemsStudy: Comparing Efficacy and Tolerability of New Daily Oral Vitamin B12 and Intermittent Intramuscular Vitamin B12
Emisphere TechnologiesSTZ-Induced Rat Model of Diabetes
Noble Life SciencesUnderstanding Sucrose: Matching Sucrose Quality to Functional Need
PfanstiehlClinical Trials: Gene Therapy
GlobalDataClinical Trials: A Round-Up of 2018
GlobalDataProtein Sciences Platform
NEOMED-LABSCompany A-Z
Clinical Trials
Alnylam begins Phase III study of patisiran in ATTR amyloidosis
Alnylam Pharmaceuticals has launched the Phase III APOLLO-B clinical trial to evaluate its RNAi therapeutic patisiran in adults suffering from transthyretin amyloidosis (ATTR amyloidosis) with...
Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial
hyperCORE International collaborates with VirTrial
Arrowhead reports initial data for cardiometabolic candidates
Novartis’ Phase III studies of ofatumumab achieve primary goals
Drug Development
Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial
US-based biopharmaceutical firm Cassava Sciences has started a Phase IIb clinical trial to assess PTI-125 for the treatment of Alzheimer’s disease.
Novartis’ Phase III studies of ofatumumab achieve primary goals
Study finds Janssen’s ponesimod superior to Sanofi’s Aubagio
Biogen finds long-term use of Tecfidera is safe and effective in MS
Lilly’s selpercatinib shows positive response in NSCLC patients
Go Top